Semaglutide can rapidly reduce heart attacks and other serious cardiovascular complications in adults with overweight or ...

Researchers have found in a new study that semaglutide could provide cardiovascular benefits to high-risk patients even ...

Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial ...

In the first direct comparison study involving individuals with obesity, tirzepatide demonstrated approximately 50% greater ...

The benefit was seen as soon as 3 months. Investigators say there should be no delaying treatment for eligible patients.

A head-to-head trial found that tirzepatide led to significantly greater weight loss and waist reduction than semaglutide in ...

Tirzepatide conferred significantly greater weight loss than semaglutide at 72 weeks for adults with overweight or obesity, ...

For the first time, scientists have pitted the two most popular weight loss drugs against each other in a direct competition ...

In the first head-to-head comparison of leading incretin-based therapies, Eli Lilly’s dual GIP/GLP-1 receptor agonist ...

Cuban annual raw sugar production will fall below 200,000 metric tons in 2025 for the first time since the 19th century, ...

New research being presented at the European Congress on Obesity (ECO 2025) has found that patients of an online obesity ...